HDAC9 and female reproductive organ cancer: Several studies have investigated the combination of HDAC inhibitors and other anticancer agents, such as carboplatin, docetaxel, gemcitabine, cisplatin, etoposide, doxorubicin, and paclitaxel in gynecological cancers.